Coagulation Factors

Coagulation Factors Market Outlook

The global coagulation factors market is anticipated to reach USD 12 billion by 2035, with a robust compound annual growth rate (CAGR) of approximately 7.5% during the forecast period of 2025 to 2035. This growth is largely driven by the increasing prevalence of bleeding disorders such as hemophilia, which necessitates the ongoing demand for effective treatment solutions. Advances in biotechnology and recombinant technologies have also played a crucial role in enhancing the efficacy and safety of coagulation factor products, thereby fostering market expansion. Furthermore, rising awareness about blood disorders and improved healthcare access in developing regions are contributing positively to the market dynamics. The surge in demand for innovative therapies and treatments tailored to individual patient needs is expected to significantly influence the growth trajectory of the coagulation factors market.

Growth Factor of the Market

One of the primary growth factors fueling the coagulation factors market is the ongoing advancements in genetic research and biotechnology. New recombinant factor products have emerged, providing more effective treatments with fewer side effects than traditional human-derived products. Additionally, an increasing understanding of genetic disorders has led to more precise diagnostic methods, allowing for earlier interventions in patients with bleeding disorders. The aging global population, with a corresponding increase in lifestyle diseases, is also contributing to the rising incidence of coagulation disorders. Furthermore, improved healthcare infrastructure, particularly in emerging economies, is facilitating better access to treatment options. Increased government funding for healthcare and initiatives aimed at improving patient education on the importance of timely treatment are further propelling market growth.

Key Highlights of the Market

• The global coagulation factors market is projected to reach USD 12 billion by 2035, with a CAGR of 7.5% from 2025 to 2035.
• Rising prevalence of hemophilia and other bleeding disorders is driving demand for coagulation factor therapies.
• Innovative recombinant technologies are enhancing treatment efficacy and patient safety.
• Aging population and lifestyle-related diseases are contributing to the growth of the market.
• Improved healthcare access in developing regions is expanding the market reach.

By Product Type

Factor VIII:

Factor VIII is one of the most critical components in the coagulation factors market, primarily used in the treatment of hemophilia A. The market for Factor VIII has seen substantial growth due to its widespread application and the introduction of novel formulations that enhance its therapeutic efficacy. With the advent of longer-acting Factor VIII products, patients now experience fewer infusions, improving their quality of life. Additionally, the increase in awareness and diagnosis of hemophilia A has further escalated the demand for Factor VIII therapies, making it a vital segment of the coagulation factors market. The continuous innovation in this segment, including the development of gene therapy solutions, positions Factor VIII as a key player in the ongoing evolution of coagulation therapies.

Factor IX:

Factor IX is crucial for managing hemophilia B and is gaining traction in the coagulation factors market. The growth of this segment is attributed to advancements in recombinant technologies, which have led to more effective and safer Factor IX products. These innovations are also facilitating the development of extended half-life therapies that reduce the frequency of administration needed for effective management of the condition. As the understanding and diagnosis of hemophilia B improve, there is a corresponding rise in the demand for Factor IX treatments, thereby reinforcing its importance in the coagulation factors market. Continuous research and development efforts to enhance product offerings are expected to sustain the growth momentum of the Factor IX segment.

Factor VII:

Factor VII plays a vital role in the coagulation pathway and is essential for patients with Factor VII deficiency and those requiring surgical interventions. This segment of the coagulation factors market is witnessing growth due to increasing awareness about bleeding disorders and advancements in treatment options. Factor VII products, particularly recombinant formulations, are being preferred for their safety profile and lower risk of viral transmission compared to traditional human-derived products. The growing demand for surgical procedures, including orthopedic and cardiovascular surgeries, has further driven the need for Factor VII, reinforcing its significance in the market. Continuous innovations and the introduction of high-purity Factor VII products are expected to enhance patient outcomes and expand the market.

Prothrombin Complex Concentrates:

Prothrombin Complex Concentrates (PCCs) are essential for managing patients with vitamin K deficiency and those on anticoagulant therapy who experience bleeding. This segment is experiencing significant growth due to the increasing incidence of anticoagulant usage and the need for rapid reversal agents in emergency settings. PCCs offer the advantage of containing multiple coagulation factors, which allows for effective management of bleeding in various clinical scenarios. The expanding applications of PCCs in surgical settings and the development of newer formulations with improved safety profiles are further propelling this segment. The strategic positioning of PCCs as first-line treatments for urgent bleeding situations underscores their importance in the coagulation factors market.

Fibrinogen Concentrates:

Fibrinogen concentrates are becoming increasingly relevant in the coagulation factors market, particularly for patients with congenital fibrinogen deficiency and those undergoing major surgical procedures. The growth of this segment is driven by the rising awareness of fibrinogen's role in hemostasis and the therapeutic benefits of fibrinogen concentrates in managing bleeding. With advancements in production methods leading to higher purity and efficacy of fibrinogen concentrates, their acceptance among healthcare professionals is rising. Moreover, the increasing number of trauma cases and surgical interventions requiring fibrinogen supplementation is further boosting demand for fibrinogen concentrates, cementing their position in the coagulation factors market.

By Application

Hemophilia A:

Hemophilia A is one of the primary applications driving the coagulation factors market, with Factor VIII being the critical therapeutic agent. The growing diagnosis rates and awareness of hemophilia A among healthcare professionals and patients have led to an increase in treatment initiation. With advancements in therapeutic options that offer better efficacy and improved safety profiles, the treatment landscape for hemophilia A is evolving rapidly. Additionally, the introduction of gene therapy approaches for hemophilia A patients is expected to revolutionize the way this disorder is managed, significantly impacting the market growth. The establishment of comprehensive care centers dedicated to hemophilia A management further enhances treatment adherence and outcomes, thus positively influencing market dynamics.

Hemophilia B:

Hemophilia B is another critical application segment within the coagulation factors market, primarily associated with the use of Factor IX. The increasing prevalence of hemophilia B and advancements in treatment options are driving this segment's growth. The introduction of extended half-life Factor IX products has transformed the treatment landscape, allowing for less frequent administration and improved patient quality of life. Moreover, ongoing clinical trials and research initiatives aimed at developing novel therapies, including gene therapy, are expected to further bolster the treatment options available for hemophilia B. Such innovations not only enhance patient outcomes but also broaden the overall market for coagulation factors.

Von Willebrand Disease:

Von Willebrand Disease (VWD) is another significant application driving the coagulation factors market, with the need for effective treatment options for this common bleeding disorder. The increasing awareness regarding VWD, along with improvements in diagnostic methods, has led to more accurate identification and treatment of affected patients. Treatment for VWD often involves the use of von Willebrand factor concentrates, which are gaining popularity due to their effectiveness in managing bleeding episodes. The rise in the number of patients diagnosed with VWD, coupled with advancements in treatment formulations, is expected to contribute positively to the market dynamics. As clinicians become more adept at managing VWD, the demand for effective coagulation factor products will continue to grow.

Factor VII Deficiency:

Factor VII deficiency is a rare but critical bleeding disorder that necessitates specific treatment strategies, thus creating a niche segment in the coagulation factors market. The growing awareness and diagnosis of Factor VII deficiency are driving the demand for tailored treatment options, including recombinant Factor VII products. Innovations in treatment formulations and delivery methods are enhancing the efficacy of Factor VII therapies, making them more accessible to patients. The establishment of specialized care guidelines and treatment protocols for managing Factor VII deficiency is further solidifying the market for these products. Additionally, ongoing research into alternative therapies is expected to expand the treatment landscape for patients suffering from this deficiency.

Others:

In addition to hemophilia A, hemophilia B, VWD, and Factor VII deficiency, there are other applications within the coagulation factors market that warrant consideration. These include various inherited and acquired bleeding disorders that require immediate and effective interventions. The growing awareness of these less common disorders and the corresponding demand for effective treatments are shaping this segment. Moreover, the continuous development of innovative therapies tailored to specific patient needs will likely enhance the market potential for these applications. As healthcare providers increasingly recognize the importance of managing diverse bleeding disorders, the overall demand for coagulation factor products will continue to rise, thereby positively impacting market growth.

By Distribution Channel

Hospitals:

Hospitals are among the primary distribution channels for coagulation factor products, significantly influencing their availability and accessibility to patients. The demand for coagulation factors in hospitals is driven by the need for immediate interventions in emergency situations, such as trauma cases or surgical procedures. Hospitals typically maintain a robust inventory of coagulation factors to ensure timely treatment for patients with bleeding disorders. Furthermore, advancements in hospital pharmacy services and collaborations with manufacturers have enhanced the procurement processes, ensuring that the latest and most effective coagulation factor products are readily available. The ongoing expansion of hospital networks and specialized hemophilia treatment centers is expected to bolster this distribution channel's growth.

Specialty Clinics:

Specialty clinics have emerged as important distribution channels for coagulation factors, particularly for patients requiring ongoing management of bleeding disorders. These clinics are often staffed by healthcare professionals with specialized knowledge in treating hemophilia and other coagulation disorders, providing a comprehensive approach to patient care. As the demand for personalized treatment plans increases, specialty clinics offer tailored therapeutic options, fostering improved patient adherence and outcomes. The growing recognition of the importance of specialized care in managing complex bleeding disorders is expected to drive the expansion of this distribution channel, making it a vital component of the coagulation factors market.

Retail Pharmacies:

Retail pharmacies play a significant role in the distribution of coagulation factors, providing convenient access to patients requiring outpatient therapies. The availability of coagulation factors in retail settings enhances accessibility for patients who may not have easy access to hospitals or specialty clinics. As patient awareness of bleeding disorders rises, demand for coagulation factor products in retail pharmacies has also increased. Furthermore, partnerships between pharmaceutical companies and retail pharmacy chains are facilitating better stocking and distribution of these critical products. The growing trend towards home healthcare and self-administration of coagulation factor therapies is expected to further enhance the importance of retail pharmacies in this market.

Online Pharmacies:

Online pharmacies are becoming increasingly significant in the distribution of coagulation factors, particularly in the context of evolving healthcare delivery models. The convenience of purchasing medications online, along with comprehensive information about products, is driving the growth of this distribution channel. Online pharmacies offer the added advantage of home delivery, making it easier for patients to access crucial coagulation factor therapies. As more patients embrace digital health solutions, the demand for online pharmacies is expected to surge. Additionally, collaborations between manufacturers and reputable online pharmacies will enhance product visibility and accessibility, thus contributing to the overall growth of the coagulation factors market.

By Ingredient Type

Human-derived:

Human-derived coagulation factors have been the traditional treatment option for patients with bleeding disorders for decades. These products, sourced from pooled human plasma, have demonstrated efficacy in managing various bleeding conditions. However, concerns regarding viral transmission and variability in product potency have prompted the development of alternative therapies. Despite these challenges, human-derived products continue to play a critical role in the coagulation factors market due to their established track record and familiarity among healthcare providers. The ongoing demand for these products, particularly in resource-limited settings, indicates that human-derived coagulation factors will remain an essential component of the treatment landscape.

Recombinant:

Recombinant coagulation factors have revolutionized the treatment of bleeding disorders by providing safer and more consistent therapeutic options. Unlike human-derived products, recombinant factors are produced through genetic engineering, significantly reducing the risk of viral transmission and other complications. The increasing preference for recombinant therapies among healthcare providers and patients is driving the growth of this segment within the coagulation factors market. Ongoing innovations, such as longer-acting formulations and combination therapies, are enhancing the appeal of recombinant coagulation factors. As patient awareness of treatment options continues to grow, the demand for recombinant factors is expected to increase, further solidifying their position in the market.

By Region

The coagulation factors market is witnessing robust growth across various regions, driven by a combination of increasing prevalence of bleeding disorders, advancements in treatment options, and improving healthcare infrastructure. In North America, the market is projected to dominate due to the presence of well-established healthcare systems and a high level of awareness regarding bleeding disorders. With an expected CAGR of approximately 8% from 2025 to 2035, North America's growth is fueled by the rising incidence of hemophilia and the introduction of innovative therapies. Furthermore, the United States is home to several leading pharmaceutical companies specializing in coagulation factors, ensuring continued advancements in treatment options and market expansion.

Europe is also a significant region in the coagulation factors market, with a strong emphasis on research and development fostering innovation in the sector. The European market is projected to experience a steady growth rate of around 6% during the forecast period, largely driven by increasing patient access to treatments and the establishment of specialized hemophilia treatment centers. Countries such as Germany, France, and the United Kingdom are at the forefront of coagulation factor research and development, contributing to market growth. In contrast, the Asia Pacific region is emerging rapidly, with a projected CAGR of 7% as governments invest in healthcare infrastructure and raise awareness of bleeding disorders, leading to a greater demand for coagulation factor therapies.

Opportunities

The coagulation factors market presents numerous opportunities, particularly in the context of technological advancements and increased patient awareness. One significant opportunity lies in the development of personalized medicine, where treatments can be tailored to meet the specific needs of individual patients. As more genetic information becomes available, there is a growing potential for targeted therapies that can optimize treatment outcomes for patients with hemophilia and other bleeding disorders. Furthermore, the expansion of telemedicine and digital health solutions provides a platform for better patient engagement, enabling healthcare providers to monitor treatment adherence and efficacy remotely. This, in turn, can lead to improved patient satisfaction and market growth as healthcare providers embrace these innovative approaches to treatment delivery.

Another key opportunity in the coagulation factors market is the rising interest in gene therapies. As research continues to advance, gene therapy has the potential to provide long-term solutions for patients with hereditary bleeding disorders, effectively reducing the burden of regular infusions of coagulation factors. The successful implementation of these therapies has the potential to revolutionize the treatment landscape, significantly impacting patient outcomes and reducing healthcare costs associated with long-term treatment. Additionally, the increasing collaboration between biotechnology firms and pharmaceutical companies will likely facilitate the development of new treatments, further enhancing the market's growth potential. Investing in research and development of next-generation coagulation factor products will provide significant competitive advantages for companies operating in this space.

Threats

Despite the opportunities, the coagulation factors market faces several threats that could hinder its growth. One of the most significant threats is the growing competition from alternative treatment modalities, such as non-factor therapies that aim to provide effective management for bleeding disorders with fewer complications. These alternative therapies could shift treatment paradigms and reduce reliance on traditional coagulation factor products. Furthermore, pricing pressures due to healthcare reforms, particularly in developed markets, may lead to challenges in maintaining profitability for manufacturers. The need for ongoing investment in research and development, coupled with potential reimbursement challenges, could pose additional hurdles for companies in the coagulation factors market, forcing them to adapt their strategies to stay competitive.

Another threat to market growth is the regulatory landscape surrounding the approval of new coagulation factor therapies. The rigorous and often lengthy process of obtaining regulatory approvals can delay the introduction of innovative products to the market. Additionally, any adverse events or safety concerns associated with coagulation factor therapies could lead to increased scrutiny from regulatory bodies, resulting in stricter regulations that may impact the availability of these treatments. The emergence of counterfeit and substandard products in some regions also poses a significant risk, potentially undermining patient trust and impacting the overall market dynamics. Manufacturers must navigate these complexities to ensure sustainable growth in the coagulation factors market.

Competitor Outlook

• CSL Behring
• Grifols, S.A.
• Baxter International Inc.
• Shire (now part of Takeda Pharmaceutical Company Limited)
• Octapharma AG
• Pfizer Inc.
• Amgen Inc.
• Bioverativ Inc. (a Sanofi company)
• Hemophilia Drug Development (HDD)
• Novo Nordisk A/S
• Sobi (Swedish Orphan Biovitrum AB)
• Hematologic Technologies, Inc.
• Ferring Pharmaceuticals
• Roche Holding AG
• Takeda Pharmaceutical Company Limited

The competitive landscape of the coagulation factors market is characterized by a diverse array of established players and emerging companies striving to capture market share through innovation and strategic partnerships. Major companies in this sector are heavily investing in research and development to introduce novel therapies that can meet the evolving needs of patients with bleeding disorders. These companies are also focusing on expanding their product portfolios and enhancing the efficacy and safety profiles of existing treatments. Collaborations, mergers, and acquisitions among key players are common strategies aimed at strengthening their market position and increasing their R&D capabilities.

CSL Behring stands out as a global leader in the coagulation factors market, with a robust portfolio of recombinant and plasma-derived therapies for hemophilia and other bleeding disorders. The company's commitment to patient care and continuous innovation has positioned it at the forefront of the industry. Baxter International Inc. is another significant competitor, known for its extensive range of coagulation factor products, including advanced therapies that target specific patient needs. The company's investments in biotechnology and collaboration with healthcare providers contribute to its strong market presence. Similarly, Grifols, S.A. and Takeda Pharmaceutical Company Limited are key players that continue to shape the market, leveraging their expertise in blood plasma-derived therapies to develop effective solutions for patients.

As the coagulation factors market evolves, emerging players are also making their mark by focusing on niche segments and developing unique treatment approaches. Companies like Bioverativ Inc. and Sobi are gaining traction by exploring innovative therapies and establishing partnerships to enhance their product offerings. The competitive environment is dynamic, with ongoing clinical trials and research initiatives paving the way for the next generation of coagulation factor therapies. With increasing patient demand for effective treatments and a growing emphasis on personalized medicine, the competitive landscape is expected to become even more vibrant in the coming years.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 CSL Behring
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Grifols, S.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Octapharma AG
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Novo Nordisk A/S
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Ferring Pharmaceuticals
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Baxter International Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Hematologic Technologies, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Hemophilia Drug Development (HDD)
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Bioverativ Inc. (a Sanofi company)
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Sobi (Swedish Orphan Biovitrum AB)
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Takeda Pharmaceutical Company Limited
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Shire (now part of Takeda Pharmaceutical Company Limited)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Coagulation Factors Market, By Application
    • 6.1.1 Hemophilia A
    • 6.1.2 Hemophilia B
    • 6.1.3 Von Willebrand Disease
    • 6.1.4 Factor VII Deficiency
    • 6.1.5 Others
  • 6.2 Coagulation Factors Market, By Product Type
    • 6.2.1 Factor VIII
    • 6.2.2 Factor IX
    • 6.2.3 Factor VII
    • 6.2.4 Prothrombin Complex Concentrates
    • 6.2.5 Fibrinogen Concentrates
  • 6.3 Coagulation Factors Market, By Ingredient Type
    • 6.3.1 Human-derived
    • 6.3.2 Recombinant
  • 6.4 Coagulation Factors Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Specialty Clinics
    • 6.4.3 Retail Pharmacies
    • 6.4.4 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Coagulation Factors Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Coagulation Factors market is categorized based on

By Product Type

• Factor VIII
• Factor IX
• Factor VII
• Prothrombin Complex Concentrates
• Fibrinogen Concentrates

By Application

• Hemophilia A
• Hemophilia B
• Von Willebrand Disease
• Factor VII Deficiency
• Others

By Distribution Channel

• Hospitals
• Specialty Clinics
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Human-derived
• Recombinant

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• CSL Behring
• Grifols, S.A.
• Baxter International Inc.
• Shire (now part of Takeda Pharmaceutical Company Limited)
• Octapharma AG
• Pfizer Inc.
• Amgen Inc.
• Bioverativ Inc. (a Sanofi company)
• Hemophilia Drug Development (HDD)
• Novo Nordisk A/S
• Sobi (Swedish Orphan Biovitrum AB)
• Hematologic Technologies, Inc.
• Ferring Pharmaceuticals
• Roche Holding AG
• Takeda Pharmaceutical Company Limited